Barrett John Martin, Berlinguer-Palmini Rolando, Degenaar Patrick
Institute of Neuroscience,Newcastle University,Newcastle upon Tyne,United Kingdom.
School of EEE,Newcastle University,Newcastle upon Tyne,United Kingdom.
Vis Neurosci. 2014 Sep;31(4-5):345-54. doi: 10.1017/S0952523814000212. Epub 2014 Aug 6.
The concept of visual restoration via retinal prosthesis arguably started in 1992 with the discovery that some of the retinal cells were still intact in those with the retinitis pigmentosa disease. Two decades later, the first commercially available devices have the capability to allow users to identify basic shapes. Such devices are still very far from returning vision beyond the legal blindness. Thus, there is considerable continued development of electrode materials, and structures and electronic control mechanisms to increase both resolution and contrast. In parallel, the field of optogenetics--the genetic photosensitization of neural tissue holds particular promise for new approaches. Given that the eye is transparent, photosensitizing remaining neural layers of the eye and illuminating from the outside could prove to be less invasive, cheaper, and more effective than present approaches. As we move toward human trials in the coming years, this review explores the core technological and biological challenges related to the gene therapy and the high radiance optical stimulation requirement.
通过视网膜假体进行视觉恢复的概念可以追溯到1992年,当时发现患有色素性视网膜炎的患者中,一些视网膜细胞仍然完好无损。二十年后,首批商业可用设备能够让用户识别基本形状。但此类设备距离恢复法定失明以上的视力仍相差甚远。因此,为了提高分辨率和对比度,电极材料、结构及电子控制机制仍在持续深入研发。与此同时,光遗传学领域——神经组织的基因光敏化,为新方法带来了特别的希望。鉴于眼睛是透明的,对眼睛剩余神经层进行光敏化并从外部照射,可能比现有方法侵入性更小、成本更低且更有效。随着我们在未来几年迈向人体试验,本综述探讨了与基因治疗以及高辐射光学刺激要求相关的核心技术和生物学挑战。